RNS60 ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症4
13多発性硬化症/視神経脊髄炎2

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02988297
(ClinicalTrials.gov)
November 20227/12/2016Nebulized RNS60 for the Treatment of Amyotrophic Lateral SclerosisNebulized RNS60 for the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: RNS60;Drug: PlaceboRevalesio CorporationNULLNot yet recruiting18 Years80 YearsAll140Phase 2NULL
2EUCTR2016-002382-62-IT
(EUCTR)
13/01/201722/06/2021The effects of RNS60 on ALS biomarkersThe effects of RNS60 on ALS biomarkers - RNS60-ALS Amyotrophic Lateral Sclerosis
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 21.1;Level: LLT;Classification code 10052889;Term: ALS;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: RNS60
Product Code: RNS60
Product Name: RNS60
Product Code: RNS60
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
142Phase 2United States;Italy
3NCT03456882
(ClinicalTrials.gov)
November 18, 20162/2/2018The Effect of RNS60 on ALS BiomarkersThe Effect of RNS60 on ALS BiomarkersAmyotrophic Lateral SclerosisDrug: RNS60Mario Negri Institute for Pharmacological ResearchALS Association;Get out ONLUSCompleted18 Years80 YearsAll142Phase 2United States;Italy
4NCT02525471
(ClinicalTrials.gov)
October 201512/8/2015A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)ALSDrug: RNS60Sabrina Paganoni, M.D.NULLCompleted18 Years80 YearsAll24Phase 1United States

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-000221-20-AT
(EUCTR)
23/10/201425/06/2014Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical TrialTreatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: RNS60
Product Code: RNS60
University Hospital ZürichNULLNot RecruitingFemale: yes
Male: yes
16Phase 2Austria;Switzerland
2NCT01714089
(ClinicalTrials.gov)
March 201319/10/2012Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple SclerosisA Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: RNS60 125 ml;Drug: RNS60 250 ml;Drug: Interferon beta 1aRevalesio CorporationNULLWithdrawn18 Years50 YearsBoth0Phase 2United States